#United States #Karyopharm #Newton #Myelofibrosis #Selinexor

Karyopharm's SENTRY Trial Presentation at EHA 2026

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a pioneering entity in the realm of cancer therapies, has announced its selection for an oral presentation at the 2026 European Hematology Association (EHA) Congress, slated to occur from June 11 to 14 in Stockholm, Sweden. The focus will be on the results from the Phase 3 SENTRY trial, which investigated the efficacy of selinexor, an innovative therapy, in conjunction with the established drug ruxolitinib in patients suffering from myelofibrosis.

The SENTRY trial stands as a significant study designed to evaluate the impact of this combination on spleen volume reduction and overall patient symptoms. Karyopharm's chosen abstract has garnered recognition as one of the top six abstracts by the EHA's Scientific Program Committee, heralding it as a critical discussion point during the Late-Breaking Oral Session on Sunday, June 14, at 9:15 a.m. to 10:45 a.m. Central European Summer Time. Dr. Claire Harrison, the Professor of Myeloproliferative Neoplasms at Guy's and St. Thomas' NHS Foundation Trust, will deliver the presentation, underscoring the trial's promising outcomes.

The SENTRY trial, a double-blind and placebo-controlled study, involved 353 participants randomized to receive 60 mg of selinexor combined with ruxolitinib or a placebo alongside ruxolitinib. Preliminary findings spotlighted the potency of this drug pairing in achieving rapid and substantial reductions in spleen volume while delivering comparable improvements in symptoms. Remarkably, there is an encouraging signal suggesting the potential increase in overall survival rates among patients who achieved a spleen volume reduction of 35% (SVR35).

Key Findings from the SENTRY Trial

Notably, the findings presented at EHA exhibit how selinexor and ruxolitinib together not only expedite symptoms relief but also provide a unique therapeutic advantage that could extend survival rates. Specific outcomes illustrate:

• - Enhanced ability to sustain spleen volume reductions,
• - Significant reductions in variant allele frequency (VAF) observed as early as week 24,
• - An overall favorable safety profile compared to standard treatments.

Dr. Harrison emphasized the pivotal role that these results could play in changing therapeutic strategies for patients with myelofibrosis, a condition affecting approximately 20,000 individuals in the United States alone. "While JAK inhibitors have transformed the treatment landscape, the need for novel therapies that target different biological pathways remains critical," she stated, alluding to the unique mechanism by which selinexor operates, setting it apart from traditional treatment options.

The insights from the Phase 1 portion of the trial further correlate with this promising survival signal, highlighting that those achieving an SVR35 are likely to experience improved overall survival rates. This reinforces Karyopharm's commitment to advancing treatment avenues that significantly improve patient outcomes.

About Myelofibrosis and Karyopharm's Role

Myelofibrosis, characterized by fibrosis or scarring of the bone marrow, presents unique challenges such as anemia and splenomegaly, leading to debilitating symptoms for those affected. Currently, JAK inhibitors like ruxolitinib are the only approved treatment classes, but Karyopharm's developments could close the gap in available therapies, harnessing selinexor’s unique mechanism to fight this debilitating disease.

Looking forward, Karyopharm will also offer a copy of the SENTRY presentation on its investor relations website following the EHA congress. The momentum gained from this research not only adds to the ongoing dialogue around innovative cancer therapies but also lays the groundwork for further studies in both hematologic malignancies and solid tumors.

For more insights, stay tuned as we continue to cover Karyopharm's journey and the evolving landscape of cancer treatment options.